aids2012 tuaa0301
DESCRIPTION
AIDS2012 TUAA0301. Pre-clinical Evaluation of HIV Replication Inhibitors that Target the HIV Integrase -LEDGF/p75 Interaction Frauke Christ , Chris Pickford, Jonas Demeulemeester, Stephen Shaw, Belete Desiemmie, Caroline Smith-Burchnell, Scott Butler, Mike Westby, Zeger Debyser - PowerPoint PPT PresentationTRANSCRIPT
AIDS2012 TUAA0301
Pre-clinical Evaluation of HIV Replication Inhibitors that Target the HIV Integrase-
LEDGF/p75 Interaction
Frauke Christ, Chris Pickford, Jonas Demeulemeester, Stephen Shaw, Belete Desiemmie, Caroline Smith-Burchnell, Scott Butler, Mike Westby, Zeger Debyser
Molecular Virology and Gene TherapyKU Leuven
Belgium
LEDGF/p75 is a co-factor of HIV integrase (Cherepanov et al, JBC, 2003) that tethers the provirus to the cellular genome.
The interface of LEDGF/p75 and integrase is well defined (Cherepanov et al. PNAS, 2005)
Overexpression of the LEDGF/p75 integrase binding domain (IBD) inhibits HIV replication (De Rijck et al., JVI, 2006)
LEDGINs, first in class allosteric integration inhibitors bind to the LEDGF/p75 binding site on integrase. (Christ, et al., Nat. Chem. Biol. 2010)
LEDGF/p75 is a novel target for antiviral therapy
LEDGINs, first-in-class antivirals 1.84 Å co-crystal structure
LEDGINs are a novel class of HIV-replication inhibitors designed on the basis of a pharmacophore model.
By combination of medicinal chemistry and structural biology different series of compounds have been developed with activities in the low nanomolar range and selectivity >5000.
LEDGINs block the LEDGF/p75-IN interaction and bind to an allosteric site on integrase.
(Christ, et al., Nat. Chem. Biol. 2010)
LEDGINs, first-in-class antiviralsName Structure LEDGF/p75-
integrase
MTT/MT-4
IC50 [µM] EC50 [µM] CC50 [µM]SI
CX051681.37±0.36 2.35±0.28 59.8±0.5 25
CX050450.58±0.30 0.76±0.08 72.2±5.15 95
CX144420.046±0.012 0.069±0.003 96.0±16.0 1391
NO
OHCl
S NO
OH
S NO
OHO
1tan28a566028 52tan28a566028 0tan28a566028 0tan19a5660190tan8a56608
0tan28a566028
0tan19a566019
0tan9a56609
0tan29a566029
0tan19a566019
0tan10a566010
0tan30a566030 Ral-tegravirSeries 1Series 2
log [compound]
% in
hibi
tion
More potent LEDGINs have been synthesized allowing for a detailed study of the mechanism of action.
All compounds binding to the LEDGF/p75 binding pocket inhibit LEDGF/p75 binding and strand transfer activity of integrase.
(Christ, et al., AAC, 2012)
What is the underlying allosteric mechanism?
LEDGINs potently inhibit the strand transfer reaction.
Inhibition of the strand transfer reaction is more efficient if compounds are added to integrase before the DNA substrate.
(Christ, et al., AAC, 2012)
What is the underlying allosteric mechanism?
compound EC50 [nM]
CX05168 1136,5±625
CX05045 3093±1784
CX14442 123±0,6
-3 -2 -1 0 1 20
20000
40000
60000
80000
CX05168CX05045CIM055138
log [µM]
rela
tive
coun
ts
LEDGINs stabilize the dimer interface of integrase and increase the melting temperature of the integrase multimer.
Oligomerization of HIV-integrase
compound TM (°C)
DMSO 48,1
CX05168 54,5
CX05045 57,3
CX14442 62,5
Melting of HIV-integrase
(Christ, et al., AAC, 2012)
LEDGINs inhibit HIV replication at the integration step (TOA)
Raltegravir, elvitegravir and LEDGINs profile nearly identical in Time of Addition studies.
0tan28a566028 0tan9a56609 0tan19a566019 0tan29a5660290tan28a566028
0tan19a566019
0tan9a56609
0tan29a566029
0tan19a566019
0tan10a566010
0tan30a566030tenofovir elvitegravirCX14442 zidovudine
Hours post infection
Per
cent
inhi
bitio
n
(Christ, et al., AAC, 2012)
LEDGINs activity against resistance mutants
LEDGINs are active against a wide range of INSTI resistant mutants. LEDGINs are active against a broad range of HIV-1 subtypes.
CX05045raltegravir
LEDGIN raltegravir capsid inhibitor
(Christ, et al., AAC, 2012)
LEDGINs activity against resistance mutants
LEDGIN resistance mutants were identified in serial passaging experiments with HIV-1 (NL4-3)
Mutations were introduced to the IN gene of NL4-3 by site directed mutagenesis
Series 2 and Series 3 are significantly less susceptible to resistance mutations of series 1
None of the LEDGINs lose activity in the presence of STI resistance mutations
Combination of LEDGINs and INSTIs
LEDGINs and raltegravir act additive with a tendency towards synergy when combined for therapy.
(Christ, et al., AAC, 2012)
LEDGINs impair the infectivity of viral particles
Alike for raltegravir mature viral particles are produced in the presence of LEDGINs but the viral particles produced in presence of CX05045 are impaired in their
infectivity LEDGINs do not only inhibit the provirus formation but alo the infectivity of newly
produced viral particles.
Production of IIIB Infectivity of IIIB
DMSO raltegravir ritonavir CX05045
(Christ, et al., AAC, 2012)
DMSO raltegravir ritonavir CX05045
Summary
LEDGINs are a novel promising class of inhibitors potently blocking HIV replication.
LEDGINs have multimodal mechanism direct inhibition of the LEDGF/p75-IN interaction
allosteric inhibition of the catalytic activity of integrase
Viral particles produced in the presence of LEDGINs are severly impaired for their infectivity.
LEDGINs act at the same step of HIV replication like INSTIs and potently block INSTI resistant strains.
Due to a lack of cross-resistance and additive effects of LEDGINs and raltegravir in combination experiments LEDGINs hold great promise for further clinical development.
Thank you….
KU LeuvenMolecular Medicine: Belete A. Desimmie, Jonas Demeulemeester, Barbara Van Remoortel, Nam Joo Van der Veken, Zeger Debyser
CD3 Leuven, CISTIM Leuven vzw: Damian Marchand, Arnaud Marchand, Dorothée Bardoit, Wim Smets, Patrick Chaltin
Pfizer WRD Sandwich Research: Chris Pickford, Stephen Shaw, Caroline Smith-Burchnell, Jenny Middleton, Kevin Whitby, Scott Butler, Mike Westby
Chemistry: David Pryde, Florian Wakenhut, Karl Gibson
We thank ViiV Healthcare, the European Commission and the IWT for their funding and support.